Recruiting

Observational Study

Sponsor:

Mayo Clinic

Code:

NCT02026388

Conditions

Primary Hyperoxaluria

Dent Disease

APRT Deficiency

Cystinuria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research.

Conditions

Primary Hyperoxaluria

Dent Disease

APRT Deficiency

Cystinuria

Study ID

NCT02026388

Start date

May, 2013

Status verified date

Jul, 2026

Completion date

Jun, 2030

Anticipated

Primary completion date

Jun, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of primary hyperoxaluria (PH) meeting one or more of the following criteria:

1. Liver biopsy documenting alanine-glyoxylate aminotransferase (AGT) activity below the normal reference range confirming PH type 1 OR Liver biopsy documenting glyoxylate reductase/hydroxypyruvate reductase (GR/HPR) activity below the normal reference range confirming PH type 2
2. Molecular genetic analysis (DNA testing) confirming mutations known to cause PH type 1, PH type 2, or PH type 3
3. Urinary oxalate excretion of greater than 0.8 mmol/1.73 m2/day (>70 mg/1.73 m2/day) in the absence of a identifiable causes of secondary hyperoxaluria, including gastrointestinal disease known to cause enteric hyperoxaluria
4. A patient in end stage kidney failure, in whom neither a liver biopsy nor mutational analysis are available must have: (a) A plasma oxalate concentration of greater than 60 umol/L and a kidney biopsy confirming extensive oxalate deposits OR (b) Evidence of systemic oxalosis
5. Participants in the previous protocol "Tissue Bank of Urine, Blood, and Tissue Samples Collected from the Patients with Primary Hyperoxaluria" 'Mayo IRB #' #80-04. They have already consented to bank their samples and that consent will serve to enroll them in this study.
  • Diagnosis of Dent disease meeting one or more of the following criteria:

1. Identified mutation of the gene that encodes for chloride exchange transporter 5 (CLCN5)
2. Low molecular weight proteinuria and hypercalciuria
3. Low molecular weight proteinuria and nephrocalcinosis
  • Diagnosis of APRT disease meeting one or more of the following criteria:

1. Suspected dihydroxyadeninuria and absent APRT enzyme activity measured in red blood cells (RBCs).
2. Homozygosity, or compound heterozygosity, for known disease-causing APRT mutations.
3. Passage of dihydroxyadenine stones (confirmed with stone analysis).
  • Diagnosis of Cystinuria meeting one or more of the following criteria:

1. Stone analysis demonstrating that the stone contains cystine
2. Increased urinary cystine excretion (>250 mg/gm creatinine)
  • Relative of someone with confirmed primary hyperoxaluria, Dent disease, APRT deficiency (also known as dihydroxyadeninuria), or cystinuria

Exclusion Criteria:

1. Stone formers who do not meet the inclusion criteria for primary hyperoxaluria, cystinuria, Dent disease, or APRT deficiency.
2. Unwilling or unable to provide consent/assent.

Study Design

Enrollment

2000 participants

Anticipated

Interventions and Outcome Measures

Arms

Primary Hyperoxaluria

Diagnosis of Primary Hyperoxaluria, or a family member of someone with this diagnosis.

Dent Disease

Diagnosis of Dent Disease, or a family member of someone with this diagnosis.

Cystinuria

Diagnosis of Cystinuria, or a family member of someone with this diagnosis.

APRT deficiency

Diagnosis of APRT Deficiency, or a family member of someone with this diagnosis.

Primary outcome measure

  • Number of samples stored in tissue bank [ Time Frame: 4 years ]

Central Contacts and Locations

Locations

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Principal Investigator:

John C Lieske, M.D.

More Information

Sponsor

Mayo Clinic

Last update posted

Jul 22, 2026

Last verified

Jul, 2026

Keywords

  • PH
  • primary hyperoxaluria
  • hyperoxaluria
  • primary oxalosis
  • Primary Hyperoxaluria Type 1
  • Primary Hyperoxaluria Type 2
  • Primary Hyperoxaluria Type 3
  • Dent
  • Dents
  • Dent Disease
  • Dent 1
  • Dent 2
  • Cystinuria
  • APRT
  • APRT deficiency
  • Biobank

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-07-22.